Annual Report 2022/23: BRAIN Biotech AG successfully executes growth strategy
The Group´s consolidated revenue increased strongly to € 55.3 million in the 2022/23 financial year.
Published
17 January 2024
Home/
Media & Resources/
Annual Report 2022/23: BRAIN Biotech AG successfully executes growth strategy
BRAIN Biotech AG, a leading provider of integrated solutions for the biologisation of industry and parent company of the BRAIN Biotech Group, has published the Group´s financial figures for the fiscal year 2022/23. The Group´s consolidated revenue increased strongly to € 55.3 million in the 2022/23 financial year. Compared with the previous year, this represents growth of 11.8 %.
Highlights from Fiscal Year 2022/23:
- Group sales grew by 11.8 %, 9.8 % all organic
- All divisions contribute to growth
- Successful execution of One-BioProducts strategy
- Strong progress on BioIncubator pharmaceutical project Deucrictibant
“More than ever, clear focus and accountability on the part of both the Management Board and our employees were crucial in making this financial year a successful one
